IPSEN (OTCMKTS:IPSEY – Free Report) – Stock analysts at HC Wainwright boosted their FY2026 earnings estimates for IPSEN in a research report issued on Tuesday, June 30th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of $3.62 per share for the year, up from their prior forecast of $3.49. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for IPSEN’s current full-year earnings is $3.77 per share. HC Wainwright also issued estimates for IPSEN’s FY2027 earnings at $4.05 EPS.
IPSEY has been the topic of a number of other reports. Zacks Research upgraded shares of IPSEN to a “hold” rating in a research report on Friday, May 29th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of IPSEN in a research report on Thursday, May 14th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold”.
IPSEN Stock Performance
IPSEY stock opened at $46.50 on Wednesday. IPSEN has a 1-year low of $29.05 and a 1-year high of $51.10. The firm has a fifty day moving average price of $47.25 and a two-hundred day moving average price of $43.87.
About IPSEN
Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.
The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).
Further Reading
- Five stocks we like better than IPSEN
- NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
- Amazon Could Be About to Reap the Rewards of a Software Spending Boom
- Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs Proof
- AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?
Receive News & Ratings for IPSEN Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IPSEN and related companies with MarketBeat.com's FREE daily email newsletter.
